CTLA4 and glioblastoma: Further TIDE analysis, aiming to predict response to ICB, revealed that patients with higher ICOS seemed to be more sensitive to ICB therapy in GBM cohorts, suggesting that ICOS can be employed to predict the response of GBM patients before anti-PD-1/anti-CTLA4 immunotherapy.